$AZ

A2Z SMART TECHNOLOGIES ($AZ) Releases Q2 2026 Earnings

A2Z Smart Technologies ($AZ) reported Q2 2026 results on Aug. 12. The company posted EPS of -$0.16, above the -$0.25 estimate, and revenue of $5.9 million, above the $5.24 million estimate. The article also cites institutional investors adding and reducing $AZ positions in recent quarters.

Original reporting
Published Aug 12, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
A2Z SMART TECHNOLOGIES ($AZ) Releases Q2 2026 Earnings — source image
Decision brief

The 30-second read

$AZBullishMed
01

Why it matters

The only actionable information is the reported beat versus analyst estimates for EPS and revenue; there is no mention of guidance, restructuring, or other new catalysts.

02

Market read

This is a company-specific earnings release with a modest positive surprise versus consensus, which can drive short-term trading around the print.

03

What to watch

Traders may need follow-up data not included here, such as guidance, backlog, gross margin, and cash burn, to judge whether the beat is sustainable.

Relevance 6/10Novelty 6/10Timing: reported Q2 2026 results on Aug 12, after the close or during the session

Background

The piece is a quantitative-style earnings recap for A2Z Smart Technologies’ Q2 2026 results.

Company-level read

Ticker impact

$AZBullishMedium confidence
Context

A2Z Smart Technologies reported Q2 2026 EPS of -$0.16, beating -$0.25 estimates, and revenue of $5.9M above $5.24M estimates.

Expected impact

Likely modest positive reaction versus consensus on the day, but magnitude is uncertain without guidance, cash flow, or forward outlook.

Evidence & confidence

The article provides a clear beat versus estimates (EPS and revenue) but no forward guidance, balance-sheet/cash-flow changes, or segment/margin drivers that would materially reset valuation.

Market effects

Limited spillover because the article lacks sector-wide signals beyond a single microcap earnings print.

No regional macro or cross-border demand signals are provided.

No global supply chain, regulation, or geopolitical linkages are mentioned.

Counterpoint

A headline EPS beat may still reflect weak underlying profitability if costs remain elevated, and the article provides no margin or cash-flow context.

Key entities

  • A2Z Smart Technologies

    Reported Q2 2026 EPS of -$0.16 (vs -$0.25 est.) and revenue of $5.9M (vs $5.24M est.).

Related articles

$AZMedAI 8/10

A2Z Reports Second Quarter 2026 Revenue of $5.9 Million

A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) reported Q2 2026 revenue of $5.9 million, up from $1.2 million, with Smart Cart revenue of $4.41 million. Gross profit rose to $2.5 million and gross margin to 42.6%. Net loss was $7.3 million. The company cited a $30 million credit line with Bank Leumi and expects $25 million in H2 smart cart revenue.

$AZMedAI 8/10

Allianz enters deal to acquire UOB asset management arm

Allianz Global Investors agreed to acquire UOB Asset Management for S$555m (US$432.7m), covering UOBAM operations in eight Asian markets. UOB and AGI will also form a distribution partnership. UOB expects a pre-tax gain of about S$330m and a CET ratio lift of 14 bps, subject to regulatory approval, with closing in 2027.

$AZMedAI 8/10

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI said it licensed Alphamab’s bispecific ADC JSKN016 for solid tumors outside Greater China in a deal worth up to $2.2 billion, including $125 million upfront, up to $2.09 billion in milestones and royalties. JSKN016 targets TROP2 and HER3 and is in Phase 3 for TNBC. Pathos also partnered with AstraZeneca on AZD4241, an ER-targeting PROTAC in preclinical testing for HR-positive, HER2-negative breast cancer.

$AZMed

Allianz Asia Holding Pte. Ltd. agreed to acquire HSBC Life Pte. Ltd. from HSBC Holdings plc for SGD 2.7 billion.

Allianz Asia Holding Pte. Ltd. agreed to acquire HSBC Life (Singapore) Pte. Ltd. from HSBC Holdings plc for SGD 2.7 billion, including SGD 2.7 billion allocated to HSBC Life’s common equity. The deal is subject to regulatory approval, with expected completion between Jan 1 and Jun 30, 2027. HSBC Life reported EBIT of SGD 118.1 million for 2025.